Study identifier:D2270C00008
ClinicalTrials.gov identifier:NCT02398747
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients with Advanced Solid Malignancies
Advanced solid malignancies
Phase 1
No
AZD2014
All
28
Interventional
20 Years - 80 Years
Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD 50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel | Drug: AZD2014 50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel |